Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 Diabetes

Miura, Yoshitaka; Yamamoto, Naoki; Tsunekawa, Shin; Taguchi, Seiko; Eguchi, Yoko; Ozaki, Nobuaki; Oiso, Yutaka

doi:10.2337/diacare.28.3.757

Cited by 96 publications

(71 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Telmisartan has already been demonstrated to have a renoprotective effect similar to that achieved with enalapril (26), and to have a good metabolic effect in diabetic patients (27). Similar results have also been observed with irbesartan (28,29).…”

Section: Discussionsupporting

confidence: 59%

Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

et al. 2006

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 59%

Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Since PPAR-γ influences gene expression involved in carbohydrate and lipid metabolism, and since ligands for PPAR-γ can improve insulin sensitivity, telmisartan could be a promising 'cardiometabolic sartan' that targets both diabetes and cardiovascular disease in patients with hypertension [7]. Indeed, a recent clinical report has shown that replacement of valsartan and candesartan by telmisartan improves insulin resistance and decreases CRP levels in hypertensive patients with type 2 diabetes [8]. In this study, we have extended these previous findings.…”

Section: Discussionmentioning

confidence: 99%

Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation

et al. 2006

View full text Add to dashboard Cite

Aims/hypothesis C-reactive protein (CRP), an acute-phase reactant produced mainly by the liver, is elevated in diabetes, thus contributing to the development and progression of atherosclerosis. However, the molecular mechanism underlying the elevation of CRP in diabetes is not fully understood. Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferatoractivated receptor-γ (PPAR-γ)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells. Methods Protein levels of the receptor for AGE (RAGE) were analysed by western blots. Gene expression was analysed by quantitative real-time RT-PCR. CRP released into the medium was measured with ELISA.

show abstract

“…Previous studies have shown that telmisartan decreases TG concentration in hypertensive patients [45][46][47] . On the other hand, it is well known that LpL plays a central role in triglyceride metabolism.…”

Section: Effects Of Telmisartan Therapy On Preheparin Lpl Mass Concenmentioning

confidence: 99%

Effect of the Angiotensin II Receptor Antagonist Telmisartan on Lipoprotein Lipase Mass in Preheparin Serum

Hatori

Takahashi

Iizuka

et al. 2008

JAT

View full text Add to dashboard Cite

Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 Diabetes

Cited by 96 publications

References 12 publications

Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation

Effect of the Angiotensin II Receptor Antagonist Telmisartan on Lipoprotein Lipase Mass in Preheparin Serum

Contact Info

Product

Resources

About